CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Address concerns with India trade/IP policies. Support Trade Promotion Authority (TPA.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Agriculture AGR
Support Safe and Accurate Food Labelling Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Copyright/Patent/Trademark CPT
Address concerns with provisions of patent litigation reform, including inter partes review.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Medicare/Medicaid MMM
Address concerns with Medicare Independent Payment Advisory Board (IPAB). Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System. Address concerns with Medicaid coverage of specialty drugs. Support creation of incentives for antibiotics development. Oppose changes to Medicare Advantage and Part D prescription drug benefit. Support Treat and Reduce Obesity Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Budget/Appropriations BUD
Labor/HHS/Ed Appropriations: NIH, biodefense/pandemic, science/math education, and strategic stockpile funding and preparation; FDA Appropriations; PTO Appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Immigration IMM
Support STEM-Ed/H-1B related provisions in any immigration reform measure.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Financial Institutions/Investments/Securities FIN
Address concerns re biomedical corporate mergers and acquisitions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Taxation/Internal Revenue Code TAX
Support repeal of medical device tax. Support extension of R&D tax credit. Oppose repeal of Orphan Drug Tax Credit. Support extension of biofuel and biodiesel tax credits.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Health Issues HCR
FDA review process consistency and predictability. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Address concerns with changes to Medicare Part B and Part D programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Medical/Disease Research/Clinical Labs MED
Support NIH research funding. Support Viral Hepatitis Testing Act. Support OPEN Act. Support Rare Disease Priority Review Voucher permanent extension. Support reforms to reduce administrative & regulatory burdens on scientific productivity, innovation & collaboration. Support reforms to support & evolve the scientific workforce continuum. Support 21st Century Cures Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.